Pharma BD Deal Intelligence
Hologen Limited / MeiraGTx Holdings plc
2025 · Co-Development · $200M · Pending
MeiraGTx entered a strategic collaboration with Hologen Limited (Hologen AI). MeiraGTx receives a $200 million upfront cash payment at closing and the parties are forming a joint venture, Hologen Neuro AI Ltd, funded with committed capital of up to $230 million from Hologen to finance development of AAV-GAD for Parkinson's disease through commercialization and earlier-stage CNS programs including AAV-BDNF for genetic obesity. MeiraGTx retains a 30% stake in the joint venture and leads clinical development and manufacturing.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Mar 13, 2025
- Deal value $200M
- Deal type Co-Development
- Therapeutic area Neurology
- Indications Parkinson's disease, genetic obesity
- Key assets AAV-GAD (Parkinson's disease), AAV-BDNF (genetic obesity), MeiraGTx manufacturing process
- Mechanism AAV gene therapy delivering GAD to the subthalamic nucleus
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Neurology deals